No Prescription |
 |
 | ||
|
Prescription Drugs 16 |
|
| ||
No Prescription » Prescription Drugs 16
TERRAMYCIN Generic Oxytetracycline Timoptic XE ophtalmic solution Generic Timolol maleate Timosol Generic Timolol maleate Tobrex Solution Generic Tobramycin TRENTAL ER Generic Pentoxiphylline Trileptal Generic Oxcarbazepine Trisul Paediatric Sugar Free Septra Trusopt Eye Drops GB Generic Dorzolamide Tugain Topical Solution Rogaine Ultraproct Generic fluocortolone pivalate Vagifem Vaginal Generic 17 oestradiol Vallergan Forte Syrup Generic Trimeprazine Tartarate VALZAAR 80 H Generic Valsartan
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|